Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | CYP19A1 | P11511 | 12/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.55 |
| ▸ | MIF | P14174 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4062450 | 0.89 | CES1 (0.61) | CES1MAOAMAOBCYP19A1CYP11B2 | |
| SCHEMBL13741459 | 0.84 | CYP19A1 (0.50) | CES1MAOAMAOBCYP19A1CYP11B2 | |
| SCHEMBL44496 | 0.82 | CES1 (0.90) | CES1MAOAMAOBCYP19A1CYP11B2 | |
| SCHEMBL29408351 | 0.82 | CES1 (0.90) | CES1MAOAMAOBCYP19A1CYP11B2 | |
| SCHEMBL29437756 | 0.82 | CES1 (0.90) | CES1MAOAMAOBCYP19A1CYP11B2 | |
| SCHEMBL11660603 | 0.80 | MAOB (0.55) | MAOAMAOBCYP19A1PKMALDH1A1 | |
| SCHEMBL6387837 | 0.79 | CYP19A1 (0.47) | CES1MAOAMAOBCYP19A1CYP11B2 | |
| SCHEMBL6388288 | 0.79 | CYP19A1 (0.47) | CES1MAOAMAOBCYP19A1CYP11B2 | |
| SCHEMBL3066734 | 0.78 | MAOA (0.87) | CES1MAOAMAOBMAPK1ALDH1A1 | |
| SCHEMBL23154411 | 0.78 | MAOA (0.67) | CES1MAOAMAOBCYP19A1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3256468-B1 | TRICYCLIC COMPOUNDS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO LTD (CN) | 2020-04-08 | — | — | EP | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| US-7557212-B2 | Tricyclic derivatives as LTD4 antagonists | LABORATORIOS ALMIRALL, S.A. (ES) | 2009-07-07 | — | — | US | disclosed |
| EP-1973882-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2008-10-01 | — | — | EP | disclosed |
| EP-1560834-B1 | NEW TRICYCLIC DERIVATIVES AS LTD4 ANTAGONISTS | ALMIRALL LAB (ES) | 2008-06-25 | — | — | EP | disclosed |
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | SCHERING CORPORATION | 2007-09-13 | — | — | US | disclosed |
| WO-2007084498-A1 | PIPERAZINE DERIVATIVES AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| EP-1458684-A2 | THERAPEUTIC HETEROCYCLES | AstraZeneca AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| EP-0270818-B1 | Benzo(5,6)cycloheptapyridines, compositions and method of use | SCHERING CORP (US) | 1994-12-28 | — | — | EP | disclosed |
| EP-0396083-B1 | Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use | SCHERING CORP (US) | 1994-11-30 | — | — | EP | disclosed |
| US-5151423-A | Antiinflammatory agents or antiallergens | SCHERING CORPORATION (US) | 1992-09-29 | — | — | US | disclosed |
| EP-0471750-A1 | HETEROCYCLIC N-OXIDE DERIVATIVES OF SUBSTITUTED BENZO 5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1992-02-26 | — | — | EP | disclosed |
| US-5089496-A | Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies | SCHERING CORPORATION (US) | 1992-02-18 | — | — | US | disclosed |
| WO-1990013548-A1 | HETEROCYCLIC N-OXIDE DERIVATIVES OF SUBSTITUTED BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1990-11-15 | — | — | WO | disclosed |
| EP-0396083-A1 | Heterocyclic N-oxide derivatives of substituted benzo[5,6]cycloheptapyridines, compositions and methods of use | SCHERING CORPORATION (US) | 1990-11-07 | — | — | EP | disclosed |
| EP-0330673-A1 | BENZO 5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1989-09-06 | — | — | EP | disclosed |
| EP-0270818-A1 | Benzo(5,6)cycloheptapyridines, compositions and method of use | SCHERING CORPORATION (US) | 1988-06-15 | — | — | EP | disclosed |
| WO-1988003138-A1 | BENZO[5,6]CYCLOHEPTAPYRIDINES, COMPOSITIONS AND METHODS OF USE | SCHERING CORPORATION (US) | 1988-05-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213340-A1 | Farnesyl protein transferase inhibitors | FNTB, FNTA, FDPS | CES1 21/4885MAOA 4189/4885MAOB 4046/4885 |
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | CES1 2955/4885MAOA 1310/4885MAOB 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.